Selank Peptide: Sequence, Research Evidence and Batch Testing

Chemical Identity

For general laboratory handling principles, see the Pureline Biolabs peptide reconstitution guide and reconstitution calculator.

The formula and molar mass above describe the neutral peptide entry recorded by PubChem.[1] Material supplied with acetate, water or another associated component may have a different total composition. The exact form tested should be stated in the batch documentation.

How Selank Relates to Tuftsin

Tuftsin is the naturally occurring tetrapeptide Thr-Lys-Pro-Arg. Selank contains the complete tuftsin sequence followed by Pro-Gly-Pro.

This relationship is why Selank is usually described as a synthetic tuftsin analogue rather than an endogenous human peptide. The added C-terminal sequence changes the molecule's length, formula and research behaviour. Findings about tuftsin should not automatically be attributed to Selank, and findings about Selank should not be treated as findings about tuftsin.

Evidence by Research Level

Selank research spans biochemical assays, cultured cells, animal experiments and small human studies. These evidence levels answer different questions and should not be combined into a single claim.

Chemical and Molecular Characterisation

Selank has a defined seven-residue sequence and molecular mass. Analytical databases record the neutral peptide as C33H57N11O9 with an average molecular mass of approximately 751.9 g/mol.[1] These values provide a reference for identity testing, but matching an expected mass alone does not prove full sequence order, purity, quantity or sterility.

The peptide contains three proline residues. Its proline-rich structure and relationship to tuftsin have made it a subject of peptide-signalling and degradation research.[4] Chemical identity is the starting point for studying Selank, not evidence of a particular biological result.

In-Vitro Research

A 2017 study examined human neuroblastoma IMR-32 cells. It reported no change in the mRNA levels of the GABAergic-system genes studied under Selank alone. When Selank was applied together with GABA, the combination largely suppressed the expression changes that GABA produced on its own: of fourteen genes altered by GABA, only one remained significantly changed once Selank was added.[3]

That result is a direct caution against reducing Selank to a claim that it simply raises GABA activity. In this model Selank did not act as a GABA agonist. It damped a GABA-driven transcriptional response, and it did nothing measurable on its own. The observed effect depended entirely on the model and experimental context, and it does not establish a clinical mechanism in humans.

Animal Research

A 2016 study administered Selank or GABA intranasally to thirty male Wistar rats and compared the resulting changes in the expression of genes involved in GABAergic neurotransmission. A positive correlation was reported between the two sets of expression changes one hour after administration (r = 0.86, p ≤ 0.05), although some genes responded to only one of the two compounds.[2]

A separate rat study reported that intranasal Selank regulated brain-derived neurotrophic factor expression in the hippocampus, measured at both protein and mRNA level.[5] Other animal work has examined behaviour, memory-related tasks, stress models and changes in gene expression within brain regions.[6]

Animal findings can help form research questions, but they cannot establish a human outcome. Species differences, experimental stressors, route, timing and measured endpoints all affect the result.

Human Research

A 2008 randomised comparative study enrolled 62 participants with generalised anxiety disorder or neurasthenia. Thirty received Selank and thirty-two received medazepam, a benzodiazepine. The authors reported broadly similar anxiolytic effects between the two, with additional antiasthenic and psychostimulant effects attributed to Selank, alongside serum enkephalin measurements.[7]

A 2014 study compared Selank with phenazepam, also a benzodiazepine, in 60 patients with phobic-anxiety and somatoform disorders (ICD-10 F40.2-9, F41.1-9, F45.0-1). It reported anxiolytic and mild nootropic effects, with the anxiolytic effect persisting for a week after treatment ended.[8]

These are the two publications most frequently cited in commercial Selank summaries, and their limits matter. Both are small. Both come from the same research community. Much of the underlying literature is available only in Russian or as brief translated abstracts, reporting does not always meet current international trial standards, and independent replication outside that community is sparse. A 2021 pharmacotherapy review classed Selank among poorly studied products.[9] These studies should not be presented as proof that Selank is an established treatment.

Evidence Summary

What Is Not Established

No published study has tested Pureline Biolabs' current Selank batch for a biological or clinical outcome. General Selank literature cannot certify the identity or performance of a particular retail vial.

What Pureline Biolabs Independently Adds

Current Pureline Batch

The values above are taken from the Janoshik report for the sample submitted from batch PLB-006. The reported amount of 10.43mg is marginally above the 10mg labelled vial size, which is consistent with normal fill tolerance. This certificate reports quantity and chromatographic purity; it does not report a separate sterility, endotoxin or stereochemical result, and none should be inferred from it. The panel is updated when Pureline changes to a new batch, and earlier reports are kept with their original batch codes rather than replaced.

The Pureline Testing Standard

Testing Methods Explained

A 99 per cent HPLC result means that approximately 99 per cent of the detected chromatographic peak area was assigned to the target peak under that method. It does not mean that the vial is 99 per cent correctly filled, 99 per cent sterile or 99 per cent safe.

Storage and Traceability

Pureline stores Selank according to the conditions printed on its label and batch documentation. The cold-chain log records storage and handling while the material remains under Pureline's control. It does not replace analytical testing and should not be described as proof that no degradation occurred.

Stability depends on the peptide form, residual moisture, container closure, temperature, light exposure and time. A general storage statement cannot supply a validated shelf life for every formulation.

Common Questions